

## Close of Shortfall Offer – Rights Issue

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (**Rhythm** or the **Company**) advises the Shortfall Offer pursuant to its pro-rata non renounceable rights issue as announced on 9 February 2024 (**Rights Issue**) closed at 5pm AEST on 14 June 2024.

A total of \$2,745,416 was raised, and the Board thanks existing and new shareholders for their support. A final summary of acceptances and funds raised is provided here:

	<b>New Shares*</b>	<b>New Options*</b>	<b>Funds \$</b>
<b>Maximum under the Rights Issue</b>	<b>66,342,777</b>	<b>33,171,389</b>	<b>\$6,634,278</b>

Entitlement acceptances under the Rights Issue	16,195,109	8,097,621	\$1,619,511
Top-Up Facility acceptances up under the Rights Issue	5,027,782	2,513,912	\$502,778
<b>Total acceptances under the Rights Issue</b>	<b>21,222,891</b>	<b>10,611,533</b>	<b>\$2,122,289</b>

Partial Underwriting of Shortfall Offer	3,616,580	1,808,290	\$361,658
Additional Shortfall Placement **	2,614,690	1,307,345	\$261,469
<b>Total received under the Shortfall Offer</b>	<b>6,231,270</b>	<b>3,115,635</b>	<b>\$623,127</b>

<b>Total received under the Rights Issue Offer</b>	<b>27,454,161</b>	<b>13,727,168</b>	<b>\$2,745,416</b>
--	-------------------	-------------------	--------------------

\* The number of New Shares and New Options Is subject to rounding.

\*\* The Additional Shortfall Placement comprises the Placement detailed in the Appendix 2A released on 7 May 2024.

- ENDS -

Authorised for release by the Board.

For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com):

<b>Dr. David Atkins</b> Chief Executive Officer	<b>Mr. Guy Carisbrooke</b> Financial Controller	<b>Mr. James Barrie</b> Joint Company Secretary
--	--	--

**Australian Registered Address**

**Directors**

### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

### **About ColoSTAT<sup>®</sup>**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT<sup>®</sup> Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT<sup>®</sup> Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.